Targeting epidermal growth factor receptor (EGFR) and downstream signaling transduction has been shown to be beneficial in the treatment of lung cancer, which accounts for 19.4% of all cancer-related deaths worldwide [1, 2]. This evidence concerns the gene EGFR and lung cancer.